138 148
[22] Karnes RJ, Choeurng V, Ross AE, et al. Validation of a genomic risk
classi
fi
er to predict prostate cancer-speci
fi
c mortality in men with
adverse pathologic features. Eur Urol. In press.
http://dx.doi.org/10. 1016/j.eururo.2017.03.036 .[23]
Glass AG, Leo MC, Haddad Z, et al. Validation of a genomic classi fi er for predicting post-prostatectomy recurrence in a community based health care setting. J Urol 2016;195:1748 – 53.
[24]
Febbo PG, Crager M, Burke E, et al. Risk of clinical recurrence and prostate cancer death associated with a 17-gene Genomic Prostate Score (GPS) value < 20In: Proceedings of the American Society of Clinical Oncology; Chicago, IL; 2017, a194099.[25]
Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203 – 13.[26]
Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932 – 42.
[27]
Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415 – 24.
E U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) 1 2 9
–
13 8
138